Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March.
H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference:
- Dr. Reid will participate in a fireside chat, which will be available for on-demand viewing starting on Wednesday, March 30, 2022 at 7:00 a.m. ET.
- Dr. Reid will also participate in a panel discussion titled, “Unlocking the path to hearing restoration with gene therapy” on Wednesday, March 30, 2022 at 1:00 p.m. ET.
Cantor Fitzgerald Virtual Rare Orphan Disease Summit:
- Dr. Reid will participate in a panel discussion titled, “Gene Therapy Pioneers: Why Experience Matters When Targeting Rare Diseases” on Tuesday, March 29, 2022 at 4:00 p.m. ET. The live panel may be accessed by conference attendees through the conference portal.
Webcasts of the H.C. Wainwright fireside chat and panel may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcasts will be available on the Company’s website for approximately 90 days following the fireside chat.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200
Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936
